title: Seroprevalence of human herpes virus-8 in renal transplant recipients: a single center study from Iran.
abstract: The long-term risk of malignancy among renal transplant patients is approximately 100 times that of the general population. Unlike North America and many European countries, Kaposi's sarcoma is the most common cancer after renal transplantation in most series reported from the Middle East. Human herpes virus-8 (HHV-8) has a major role in the pathogenesis of Kaposi's sarcoma. The risk of posttransplantation Kaposi's sarcoma is 23% to 28% among seropositive patients compared with 0.7% among seronegative patients. This study was conducted to investigate the seroprevalence of HHV-8 among our transplant recipients. The sera from 100 renal transplant recipients were examined by indirect immunofluorescence against latent nuclear antigen. Sixty of 100 patients were males. The overall mean age was 41.1 years (range, 17-74 years) with 17 patients older than 55 years. The mean transplantation duration was 41.6 months. Twenty-five percent of patients were seropositive for HHV-8. There was statistically significant seropositivity for HHV-8 among recipients older than 55 years (P=.02). Eight of 17 patients older than 55 years were seropositive (47%), whereas 17/83 patients younger than 55 years were seropositive (20%). There were no significant differences for HHV-8 seropositivity regarding sex, transplantation duration, and immunosuppressive regimen, including dose of immunosuppressive drugs and cyclosporine blood levels. In this study, we showed seropositivity for HHV-8 among a significant percentage of our renal transplant recipients, a finding which may render them at risk to develop Kaposi's sarcoma. Seropositive and seronegative patients were followed for 16 months. One HHV-8 seropositive patient (1/25) developed Kaposi's sarcoma.
authors.affiliation: Urmia University of Medical Sciences, Urmia, West Azarbayjan, Iran. pedram.ahmadpoor@gmail.com
authors.forename: P
authors.initials: P
authors.lastname: Ahmadpoor
authors.forename: B
authors.initials: B
authors.lastname: Ilkhanizadeh
authors.forename: P
authors.initials: P
authors.lastname: Sharifzadeh
authors.forename: K
authors.initials: K
authors.lastname: Makhdoomi
authors.forename: A
authors.initials: A
authors.lastname: Ghafari
authors.forename: A
authors.initials: A
authors.lastname: Nahali
authors.forename: Z
authors.initials: Z
authors.lastname: Yekta
authors.forename: F
authors.initials: F
authors.lastname: Noroozinia
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003430:Cross-Sectional Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006566:Herpesviridae Infections / Q000453:epidemiology*; D019288:Herpesvirus 8, Human / Q000302:isolation & purification*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D007492:Iran; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D016036:Seroepidemiologic Studies
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents